Surviving the financial climate
Earlier disease detection will save healthcare services
Earlier disease detection will save healthcare services
The ICNC meeting attracs a lot of attention since there is a focus on PET and CT.
PET/CT combines PET's ability to precisely measure regional myocardial blood flow with the capability of multislice CT imaging.
Positron emission tomography (PET) is a fancy tool for metabolic imaging. This week Tom Lewellen from the University of Washington Medical Center in Seattle takes a detailed look on what is to expect of the recent developments in PET detector technology.
By Professor Maximilian F Reiser, director of the Institute of Clinical Radiology at the University Clinic, Munich, Germany
Dr Hanns-Joachim Weinmann, Diagnostics and Radiopharmaceuticals, Magnetic Resonance Imaging & X-Ray Research, Schering AG, examines what is feasible and what still lies only at a tantalising distance.
USA - Using positron emission tomography (PET) scanning rather than other types of imaging as the first tool to diagnose heart-vessel blockages is more accurate, less invasive and saves money, according to researchers reporting at the American College of Cardiology's Annual Scientific Session in March.
12 distinguished researchers and industry representatives presented the latest molecular medicine research at the Molecular Medicine - from Diagnostics to Therapy symposium - one in a series of annual diagnostics seminars organised by the Forum Medicine Technology & Pharmaceutics e.V.
Dr Robert Krieg, Director of MR Molecular Imaging at Siemens Medical Solutions, described, in an interview with Daniela Zimmermann of European Hospital, the limitations of physics and the potential clinical benefits of hybrid technology - and a hitherto hush-hush MRI-PET project
When it was suggested, during our interview with Dr Torsten Kuwert, Director and Professor of Clinical Nuclear Medicine, Clinic of Nuclear Medicine, at Friedrich-Alexander University Hospital, Erlangen, that SPECT-CT is the little sister of PET-CT, and that he might have preferred to install the ‘big brother’, Dr Kuwert pointed out the greater cost of PET, explaining: ‘The isotopes are more…
Generating targeting agents for diagnostics, prognostics and radiotherapy, by designing biochemically specific elements in contrast agents to be the targeting molecules attached to and carrying diagnostic or radiotherapeutic molecules to abnormal cells.
Member of the Board of the ECR Professor Malgorzata Szczerbo-Trojanowska, is Chairman of the Department of Radiology and Head of the Department of Interventional Radiology, at the University Medical School, in Lublin, Poland. The professor has carried out research in Italy, the UK, Sweden and Germany and is a member of many Polish radiological organisations, as well as the Cardiovascular and…
During the annual meeting of the Society of Nuclear Medicine, in California this June, GE Healthcare announced the first installations of its new Discovery VCT - described as “the world's first true 64-slice combination positron emission tomography and volume computed tomography (PET/CT) system.”
Late in November and into early December, as icy air streamed over the shores of Lake Michigan - affirming the nickname `windy city´ for Chicago - radiologists continued to immigrate here en masse for their biggest annual gathering. This year the Radiological Society of North America (RSNA) held its 91st annual meeting, parallel with the scientific congress and trade fair. The exhibition alone…
Combining multislice CT equipment with procedures used in nuclear medicine such as PET-CT (positron emission tomography) and SPECT-CT (single photon emission computed tomography) offers fascinating perspectives of capturing morphological image and functional diagnostics.
X-ray computed tomography (CT) has shown an absolutely remarkable and impressive increase in its performance characteristics for many years - remarkable because the modality was declared dead in the 1980s, impressive because these developments seemed impossible to many, for technical and for physics reasons.
More sensitive dissemination tests are needed for patients with locoregionally recurrent (LRR) breast cancer, according to a paper by Dutch researchers published online by the European Journal of Cancer (Volume 40, Issue 10 , 7/2004).